Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaxelis + Hib-MCC vaccine
- Development stage
- Unknown
- Lead developer
- MCM Vaccine Co
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Vaxelis + Hib-MCC vaccine refers to a combination immunization regimen or co-administration strategy developed by MCM Vaccines B.V., a joint venture between Merck Sharp & Dohme and Sanofi Pasteur. The regimen consists of Vaxelis (V419), a hexavalent vaccine containing diphtheria and tetanus toxoids, acellular pertussis antigens, inactivated poliovirus, Haemophilus influenzae type b (Hib) polysaccharide conjugated to meningococcal protein, and hepatitis B surface antigen, alongside a bivalent Hib-MCC conjugate vaccine (targeting Hib and Neisseria meningitidis serogroup C). This combination is designed to provide comprehensive active immunization in infants and toddlers against seven major infectious diseases: diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, invasive Hib disease, and serogroup C meningococcal disease. Clinical evaluation (e.g., NCT01553279) has focused on the safety and immunogenicity of administering these vaccines as part of a coordinated pediatric schedule.
- Other names
- DTaP-IPV-Hib-HepB + Hib-MenC vaccineV419 + Hib-MCC
02
Targets
PRN (Pertactin)Diphtheria toxinPRP (Haemophilus influenzae type b capsular polyribosylribitol phosphate)HBsAg (Hepatitis B surface antigen)OmpC (Outer membrane porin C)Neisseria meningitidis group C capsular polysaccharidePoliovirus type 1 capsid D-antigenPoliovirus type 2 capsid proteinPoliovirus type 3 capsid D-antigenFIM2/FIM3 (Fimbriae types 2 and 3)FHA (Filamentous hemagglutinin)PRNP (Cellular Prion Protein)Poliovirus capsid proteinsTT (Tetanus toxoid)
Beyond the preview
Go deeper on Vaxelis + Hib-MCC vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaxelis + Hib-MCC vaccine.